SLC5A2 and diabetes mellitus: Furthermore, SGLT2 inhibitors also reduce hyperglycemia-induced glucotoxicity, which refers to the ability of excess glucose to impair both insulin secretion and insulin action, leading to a vicious cycle of worsening glycemic control in diabetes mellitus.